Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: Pharsight Inks Deal to Supply Aventis with Software and Support

SAN FRANCISCO, April 30 - Pharsight said today that it will supply software and support to Aventis Pharma for clinical development of four of the pharmaceutical company's drug candidates.


The multi-year deal caps a one year proof-of-product period where Pharsight applied modeling and simulation to an Aventis project, Pharsight said.


Aventis' software integrates its computer-based modeling of scientific, clinical, commercial, and financial information about a drug candidate to create models and simulations to help steer drug development.


Details of the agreement were not disclosed.


Pharsight said this was its largest customer deal to date.


For more information, click here.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more